Affiliation Model of the Elizabeth Glaser Pediatric AIDS Foundation
This brief describes EGPAF's work to create three local and sustainable affiliate organizations in Côte d'Ivoire, Mozambique and Tanzania.
Temporal Trends in Mortality and Loss to Follow-up Among Children Enrolled in Côte d’Ivoire’s National Antiretroviral Therapy Program
During 2004-2008, >2000 children (<15 years old) initiated antiretroviral therapy (ART) in Côte d'Ivoire. Nationally representative outcomes, temporal trends in outcomes during 2004-2008 and site-level outcome determinants have not been investigated.
90-90-90 Targets For HIV-Positive Children
Facts on UNAIDS 90-90-90 treatment targets (90% of people living with HIV will know their HIV status, 90% of people who know their status will receive treatment, and 90% of people on treatment having a suppressed viral load by 2020) and how these targets apply to children.
Addressing the Social and Behavioral Barriers to Prevention of Mother-to-Child Transmission of HIV Through Community Dialogue - An Implementer's Guide Based on the Elizabeth Glaser Pediatric AIDS Foundation's Swaziland Experience (July 2012)
This technical brief examines EGPAF's approaches in Swaziland to involve communities in HIV education, prevention, care, and treatment efforts.
Facts About EGPAF’s Public Policy and Advocacy Work
This fact sheet illustrates how EGPAF advocates for change and support in the field of HIV.
What will it take to eliminate pediatric HIV? Reaching WHO target rates of mother-to-child HIV transmission in Zimbabwe: a model-based analysis
This study investigated uptake of prevention of mother-to-child HIV transmission services, infant feeding recommendations, and specific drug regimens necessary to achieve elimination of mother-to-child transmission of HIV in Zimbabwe.
What’s next in ending pediatric AIDS? June 2014 Meeting Report
This issue brief documents the discussion that took place at a policy roundtable hosted by EGPAF . The event – “What’s Next In Ending Pediatric AIDS” – brought together an impressive line-up of global health and HIV/AIDS experts to discuss progress in eliminating new pediatric HIV infections, how to improve pediatric HIV treatment and retention, unique opportunities for developing new pediatric medicines and potentially a cure, and what all of this means for children impacted by the pandemic moving forward.
Pregnancy outcomes and birth defects from an antiretroviral drug safety registry for women in South Africa and Zambia
This study evaluates the safety of combination antiretroviral therapy in conception and pregnancy in different health systems.